These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 18052761)

  • 21. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.
    Müller T; Kuhn W
    Eur J Clin Pharmacol; 2006 Jun; 62(6):447-50. PubMed ID: 16758261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
    Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K;
    Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease.
    Entacapone to Tolcapone Switch Study Investigators
    Mov Disord; 2007 Jan; 22(1):14-9. PubMed ID: 17089403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.
    Jorga K; Banken L; Fotteler B; Snell P; Steimer JL
    Clin Pharmacol Ther; 2000 Jun; 67(6):610-20. PubMed ID: 10872643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group.
    Hauser RA; Molho E; Shale H; Pedder S; Dorflinger EE
    Mov Disord; 1998 Jul; 13(4):643-7. PubMed ID: 9686768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New pharmacotherapy for Parkinson's disease.
    Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
    Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
    J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
    Limousin P; Pollak P; Pfefen JP; Tournier-Gervason CL; Dubuis R; Perret JE
    Clin Neuropharmacol; 1995 Jun; 18(3):258-65. PubMed ID: 8635184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.
    Nyholm D; Johansson A; Lennernäs H; Askmark H
    Eur J Neurol; 2012 Jun; 19(6):820-6. PubMed ID: 22136163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolcapone improves sleep in patients with advanced Parkinson's disease (PD).
    Ebersbach G; Hahn K; Lorrain M; Storch A
    Arch Gerontol Geriatr; 2010; 51(3):e125-8. PubMed ID: 20381177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolcapone: COMT inhibition for the treatment of Parkinson's disease.
    Fahn S
    Neurology; 1998 May; 50(5 Suppl 5):S1-2. PubMed ID: 9591515
    [No Abstract]   [Full Text] [Related]  

  • 32. Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease.
    Lees AJ
    CNS Neurosci Ther; 2008; 14(1):83-93. PubMed ID: 18482101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extending levodopa action: COMT inhibition.
    Martínez-Martín P; O'Brien CF
    Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice.
    Marsala SZ; Gioulis M; Ceravolo R; Tinazzi M
    Clin Neuropharmacol; 2012; 35(4):185-90. PubMed ID: 22805229
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease.
    Schapira AH; Obeso JA; Olanow CW
    Neurology; 2000; 55(11 Suppl 4):S65-8; discussion S69-71. PubMed ID: 11147512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [COMT inhibition with tolcapone].
    Nervenarzt; 1996 Jul; 67(7 Suppl Comt-hemmu):1-8. PubMed ID: 9404535
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat.
    Haasio K; Sopanen L; Vaalavirta L; Lindén IB; Heinonen EH
    J Neural Transm (Vienna); 2001; 108(1):79-91. PubMed ID: 11261749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolcapone: a novel approach to Parkinson's disease.
    Micek ST; Ernst ME
    Am J Health Syst Pharm; 1999 Nov; 56(21):2195-205. PubMed ID: 10565698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.
    Muhlack S; Herrmann L; Salmen S; Müller T
    J Neural Transm (Vienna); 2014 Nov; 121(11):1357-66. PubMed ID: 24770794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Practical issues with COMT inhibitors in Parkinson's disease.
    Waters C
    Neurology; 2000; 55(11 Suppl 4):S57-9; discussion S60-4. PubMed ID: 11147511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.